| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Howze Yalonda | INTERIM CEO & PRESIDENT | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE | /s/ Shawna-Gay White, Attorney-in-Fact | 04 Feb 2026 | 0001828153 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GBIO | Common Stock | Options Exercise | +1,673 | +65% | 4,254 | 02 Feb 2026 | Direct | F1 | ||
| transaction | GBIO | Common Stock | Tax liability | $2,792 | -495 | -12% | $5.64 | 3,759 | 02 Feb 2026 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GBIO | Restricted Stock Units | Options Exercise | $0 | -1,673 | -100% | $0.000000 | 0 | 02 Feb 2026 | Common Stock | 1,673 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | Each restricted stock unit represents the right to receive one share of the company's common stock. |
| F2 | The grant of 53,550 restricted stock units was made on April 5, 2023. Pursuant to the terms of that certain Agreement and Plan of Merger, by and among the Issuer, XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp., dated as of December 15, 2025 (the "Merger Agreement"), prior to the effective time of the merger as contemplated by the Merger Agreement, each restricted stock unit of the Issuer that was outstanding and unvested became vested in full on February 2, 2026. |